Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
eFFECTOR Therapeutics, Inc. EFTR
$0.62
+$0.09 (14.31%)
На 18:04, 12 мая 2023
+61.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
21934141.00000000
-
week52high
2.97
-
week52low
0.34
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.30350400
-
EPS
-0.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 11 авг 2022 г. |
| Credit Suisse | Outperform | Outperform | 17 мар 2022 г. |
| Stifel | Hold | Buy | 25 янв 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 25 янв 2022 г. |
| Credit Suisse | Outperform | Outperform | 25 янв 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 17 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 янв 2023 г. |
| Credit Suisse | Outperform | Outperform | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gallagher Brian M. Jr. | A | 50938 | 50938 | 20 янв 2023 г. |
| Smither John W | A | 36875 | 36875 | 20 янв 2023 г. |
| Klencke Barbara | A | 28125 | 28125 | 20 янв 2023 г. |
| Harrington-Smith Kristen | A | 28125 | 28125 | 20 янв 2023 г. |
| Bhatt Elizabeth | A | 30000 | 30000 | 20 янв 2023 г. |
| Ehrlich Christopher B | A | 35938 | 35938 | 20 янв 2023 г. |
| WORLAND STEPHEN T | A | 1000000 | 1000000 | 17 янв 2023 г. |
| Warner Douglas J | A | 250000 | 250000 | 17 янв 2023 г. |
| Byrnes Michael | A | 500000 | 500000 | 17 янв 2023 г. |
| Gandhi Mayank | A | 150000 | 150000 | 17 янв 2023 г. |
Новостная лента
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
GlobeNewsWire
30 янв 2023 г. в 08:00
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
31 окт 2022 г. в 14:05
SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:
eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference
GlobeNewsWire
21 сент 2022 г. в 09:00
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET - - Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -
eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 08:30
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference.
4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More
Benzinga
28 июн 2022 г. в 07:58
U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.